ArticleJournal of cardiothoracic surgery2026
Beta-Blocker therapy improves survival after concomitant septal myectomy and aortic valve replacement.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Forward Dynamics: Modern Insights into Mitral Systolic Anterior Motion.Journal of cardiovascular development and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coexistence of hypertrophic obstructive cardiomyopathy (HOCM) and aortic stenosis (AS) often requires concomitant septal myectomy and aortic valve replacement (AVR). However, data on outcomes and medical management remain limited. This study investigates the impact of beta-blockers on long-term survival in patients undergoing concomitant septal myectomy and AVR.
methodsWe conducted a retrospective cohort study of 55 patients with moderate-to-severe AS and HCM who underwent myectomy and AVR at our center from 2007 to 2021. We evaluated baseline characteristics, postoperative data, and survival. Kaplan-Meier and Cox proportional hazards analyses identified predictors of survival.
resultsThe mean age was 74 ± 8 years and 67% were female. Severe AS was present in 84% and 53% had HOCM. Cardiovascular risk factors were prevalent, including hypertension (80%), dyslipidemia (82%), and smoking history (53%). Postoperatively, 55% of patients experienced complications, including new-onset atrial fibrillation (35%) and complete heart block requiring permanent pacemaker implantation (33%). Beta-blocker use increased from 65% at admission to 84% at discharge. Median survival was 9.7 years, with 5-year and 8-year mortality rates of 22% and 49%, respectively, significantly lower than an age- and sex-matched control cohort (median survival 12.5 years). Beta-blockers were independently associated with improved survival (HR 0.27, 95% CI: 0.12–0.67) while smoking history predicted mortality (HR 4.07, 95% CI: 1.76–10.54).
conclusionBeta-blockers improved survival following septal myectomy and AVR while smoking history predicted mortality. Despite reduced outflow gradients, postoperative complications were common, emphasizing the need for improved treatment strategies. Further studies are needed to optimize postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.